Armata Pharmaceuticals (ARMP) Total Current Liabilities (2013 - 2026)

Armata Pharmaceuticals has reported Total Current Liabilities for 14 years, with the latest figure at $9.2 million in Q1 2026.

• Quarterly Total Current Liabilities fell 91.65% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (down 91.65% YoY) and the FY2025 annual result came in at $8.9 million, down 81.46% from the prior year.
• Total Current Liabilities advanced to $9.2 million in Q1 2026 per ARMP's latest filing, from $8.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $140.0 million in Q3 2025 and troughed at $6.2 million in Q1 2022.
• A 5-year average of $57.4 million and a median of $48.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities surged 725.81% in 2023, then slumped 91.65% in 2026.
• Over 5 years, Total Current Liabilities stood at $24.9 million in 2022, then tumbled by 33.82% to $16.5 million in 2023, then jumped by 193.11% to $48.2 million in 2024, then slumped by 81.46% to $8.9 million in 2025, then rose by 3.14% to $9.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.2 million, $8.9 million, and $140.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.